A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 141,900 shares of RNA stock, worth $4.45 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
141,900
Previous 377,400 62.4%
Holding current value
$4.45 Million
Previous $15.4 Million 57.73%
% of portfolio
0.01%
Previous 0.03%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$37.21 - $48.14 $8.76 Million - $11.3 Million
-235,500 Reduced 62.4%
141,900 $6.52 Million
Q2 2024

Aug 09, 2024

BUY
$22.73 - $40.85 $8.58 Million - $15.4 Million
377,400 New
377,400 $15.4 Million
Q4 2023

Feb 13, 2024

BUY
$4.87 - $9.37 $564,433 - $1.09 Million
115,900 Added 104.6%
226,700 $2.05 Million
Q3 2023

Nov 14, 2023

BUY
$6.3 - $11.35 $282,870 - $509,615
44,900 Added 68.13%
110,800 $707,000
Q2 2023

Aug 11, 2023

SELL
$10.62 - $17.34 $3.28 Million - $5.36 Million
-309,200 Reduced 82.43%
65,900 $731,000
Q1 2023

May 12, 2023

BUY
$15.35 - $25.65 $3.2 Million - $5.35 Million
208,500 Added 125.15%
375,100 $5.76 Million
Q4 2022

Feb 13, 2023

BUY
$10.06 - $22.66 $428,556 - $965,316
42,600 Added 34.35%
166,600 $3.7 Million
Q3 2022

Nov 14, 2022

BUY
$15.46 - $23.43 $242,722 - $367,851
15,700 Added 14.5%
124,000 $2.03 Million
Q2 2022

Aug 12, 2022

BUY
$11.18 - $20.5 $781,482 - $1.43 Million
69,900 Added 182.03%
108,300 $1.57 Million
Q1 2022

May 13, 2022

BUY
$14.2 - $23.78 $380,560 - $637,304
26,800 Added 231.03%
38,400 $709,000
Q4 2021

Feb 11, 2022

BUY
$20.4 - $28.66 $236,639 - $332,456
11,600 New
11,600 $276,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.63B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.